Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma

NEXT STORY
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
PREV STORY
CareDx Enhances Leadership Team with Key Appointments
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES ...

author_avatar
NASDAQ Market News

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome

LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ...

author_avatar
NASDAQ Market News

Research From Exergen Corporation Shows Morning-Only Temperature Readings May Miss up to Half of All Fevers

author_avatar
NASDAQ Market News